ClinicalTrials.gg
RecruitingNCT06983119C-FiND PaviaUpdated May 21, 2025

Case-Finding for Neurocognitive Disorders in Pavia

An interventional study of Case-finding for Neurocognitive Disorders in Dementia and Mild Cognitive Impairment, sponsored by IRCCS National Neurological Institute "C. Mondino" Foundation. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-21.

Sponsored by IRCCS National Neurological Institute "C. Mondino" Foundation · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Jul 2024, registered Apr 2025).
  • Started Jul 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
490
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Dementia is a global public health challenge with a heavy caregiving burden, impacting families, communities, and healthcare systems. It is a priority in healthcare planning, with focus on early diagnosis and ongoing support. This research project addresses the global public health challenge posed by dementia, focusing on early detection and comprehensive care. The research evaluates the clinical, social, and healthcare impact of two dementia-related projects in Italy:

  1. the first "Ricor-Dare," aims to create an integrated network for identifying new cases of dementia or Mild Cognitive Impairment (MCI) and providing care to patients and caregivers;
  2. the second involves establishing a new Center for Cognitive Disorders and Dementia (CCDD) in an area previously lacking such services.

The primary goal of this study is to assess the effectiveness of case-finding strategies promoted by the "Ricor-Dare" project for the early detection of cognitive decline. Researchers will compare three different settings in which case-finding will be conducted: at the general practitioners' offices, at the Dementia Operations Center, and at Open Days for the general population. The aim is to measure how many individuals in these three settings are diagnosed with Mild Cognitive Impairment (MCI) or dementia, compared to those identified as potential cases through cognitive testing.

The secondary goal of the study is to assess the social, care, and prevention impact of the activities offered within the two projects. This includes evaluating the experiences of patients and families who access the new CCDD in the province of Pavia, the impact of care pathways on caregivers, and comparing the effectiveness of the new CCDD with existing ones in the region of Lombardia. The study will also assess the role of the "Ricor-Dare" project in addressing the needs of patients, caregivers, and professionals, as well as the effectiveness of awareness-raising and training activities on dementia. Overall, the study aims to provide valuable insights into improving care for people with dementia and supporting their families and caregivers.

Read the detailed description

Dementia is currently one of the most urgent challenges that global public health must address, with a significant caregiving burden that deeply impacts families, communities, and healthcare systems. It is a key priority in healthcare and social care planning worldwide, with growing emphasis on early diagnosis and appropriate support throughout the course of the disease. According to the World Health Organization, more than 55 million people globally have been diagnosed with dementia, and this number is expected to rise to 139 million by 2050. In Italy, approximately one million people are affected by dementia, and around 900,000 have MCI, with more than three million people directly or indirectly involved in caregiving. However, in high-income countries, the proportion of diagnosed cases remains relatively low, with estimates suggesting that only 20-50% of documented cases are diagnosed in primary care settings. The province of Pavia has 539,239 inhabitants, with an estimated 11,300 individuals diagnosed with dementia and 9,000 with MCI. Consistent with international literature, the ratio of observed to expected cases of dementia and MCI suggests a significant underestimation. Timely diagnosis of the disease or risk of disease enables the person and their caregivers to make informed choices, plan for the future, and gain access to treatments that can help manage symptoms. Centers for Cognitive Disorders and Dementia (CCDD) are healthcare services that play a critical role in the management of dementia and cognitive disorders. Scientific evidence shows that timely access to a specialized cognitive assessment and diagnostic service can lead to better outcomes for individuals with cognitive decline and their families, and be cost-effective for the healthcare system. An accurate and timely diagnosis, support for individuals with dementia and their families, along with early intervention by a multidisciplinary team of healthcare professionals, can have a positive impact on maintaining functional abilities and delaying cognitive decline and institutionalization.

The overall goal of this study is to assess the social and health impact of various services and actions aimed at individuals with cognitive decline within two projects initiated in Italy, specifically in in the Pavia area located in northern Italy: the "Ricor-Dare: integrated territorial network for dementia" project and the opening of a new Cognitive Disorders and Dementia Center (CCDD) Lomellina by Fondazione Mondino in the city of Vigevano. Specifically, the primary goal of this study is to measure the effects of case-finding strategies for the timely detection of dementia in its prodromal or early stages across three different settings. The secondary aim of this study is to evaluate and monitor the social and care effects of the activities offered within the two projects, aimed at patients, caregivers, healthcare professionals, and the community, through a series of indicators reflecting social and health care. This objective will allow for the evaluation, through a set of indicators, of the impact of these complex social and health care, and social actions both on patients identified through case-finding activities and on patients attending the new CCDD Lomellina in the province of Pavia.

For the primary goal of this study, the investigators will evaluate the impact of different case-finding strategies in identifying patients with MCI or dementia. These strategies will be implemented across three different settings:

  1. General Practitioners (GPs) Offices: With their in-depth knowledge of their patients' medical histories, GPs play a crucial role in identifying those at risk of dementia or exhibiting cognitive symptoms. Using tools like the GP Cognitive Assessment of Cognition (GPcog), GPs can detect early signs of cognitive decline and refer patients for further evaluation at a CCDD. As part of the study, two annual conferences will be organized to train GPs on neurodegenerative diseases, dementia risk factors, and the GPcog. Patients scoring at the GPcog below 5 or in the borderline range (5-8) will be referred for a second-level neuropsychological evaluation at the CCDD. Additionally, a neuropsychologist will visit selected GP offices three times a year. During these visits, the neuropsychologist will conduct interviews, assess risk factors using the Lifestyle for BRAin health (LIBRA), and perform cognitive evaluations using the Addenbrooke's Cognitive Examination-III (ACE-III). Patients with below-normal or borderline ACE-III scores will be recommended for further CCDD evaluation. This initiative aims to enhance GPs' awareness of case-finding tools in their routine practice.
  2. Information desk of the Dementia Operations Center (COD): The COD information desk offers a free public service aimed at the early management of citizens reporting subjective cognitive disturbances that may indicate prodromal or early-stage dementia. The case-finding strategy at the COD involves enrolling all citizens who independently report subjective cognitive disturbances without a prior diagnosis of cognitive decline. Specifically, a neuropsychologist will conduct an interview to collect demographic and medical history information, as well as dementia risk factors through the LIBRA Index, and carry out a first-level neuropsychological assessment through the ACE-III. Those scoring below the norm or borderline will be recommended for further evaluation at the CCDD.
  3. Open Days: The Open Days are territorial initiatives for citizen designed for the early management of reports regarding subjective cognitive disturbances that could indicate prodromal or early-stage dementia. The case-finding strategy for Open Days involves organizing approximately two events per year, aimed at early detection of cognitive disturbances. During the Open Day, a neuropsychologist will conduct an interview to collect demographic and medical history information, as well as risk factors for dementia through the LIBRA Index, and perform a first-level neuropsychological assessment through the ACE-III. Those scoring below the norm or borderline will be recommended for further evaluation at the CCDD.

For the secondary goal of the study, the investigators will assess the experiences of patients and families who access the new CCDD in the province of Pavia, the impact of care pathways on caregivers, and comparing the effectiveness of the new CCDD with existing ones in the region of Lombardia. Below a detailed description of the six secondary outcomes are presented:

  1. Explore the effect of the opening of a new CCDD. Assessing the role and contribution of the new CCDD in the management and care of individuals with dementia and MCI comparing data with other CCDDs in the Lombardy region. At the new CCDD, various diagnostic and care services are offered for patients with cognitive impairment. These include a neurological consultation to assess cognitive deterioration, followed by additional tests such as neuropsychological evaluations, neuroimaging, and advanced diagnostics at the Mondino Foundation. Multidisciplinary consultations, such as geriatrics and psychiatry, may also be recommended based on the neurologist's discretion. After the diagnostic process, patients and their families receive a joint consultation with a neurologist and psychologist to discuss the diagnosis and define a care plan. This care plan encompasses pharmacological treatments, including regular follow-ups for adjusting medications, and non-pharmacological treatments, such as individual or group cognitive stimulation. To evaluate the impact of the new CCDD's activity, data will be collected on the number of patients assessed, their diagnoses, and the services provided. An online questionnaire based on the National Survey on Cognitive Disorders and Dementia Centers will be administered to the CCDD Mondino Lomellina and Mondino Pavia to gather this data. The responses will be compared with previous survey results and regional benchmarks.
  2. Explore the experience of people with cognitive decline and their caregivers accessing the new CCDD to evaluate the social and healthcare impact of opening a new CCDD. This will provide insights into challenges and needs, helping improve support throughout the diagnostic and care process. To achieve this, two methods will be employed. The first involves administering tailored questionnaires to both patients with mild dementia or MCI and their caregivers after their first follow-up visit at the CCDD. The second method includes conducting an online focus group with at least 10 caregivers, providing an opportunity to discuss their experiences with the new clinical care setup.
  3. Evaluate the impact and effectiveness of diagnostic and care pathways specifically designed for caregivers, offered in the "Ricor-Dare" project and through routine clinical practice at the new CCDD. This action involves three phases: an initial evaluation (pre-test) of caregivers' burden (Zarit Burden Interview) and caregivers' preparedness to assess their perceived readiness to manage the physical and emotional needs of their loved ones (Caregiver Preparedness Scale), followed by tailored support interventions (individual psychological support, psychoeducational groups, Alzheimer's café), and a final evaluation (post-test) with the same questionnaires use in the pre-test session to assess the effectiveness of the interventions.
  4. Evaluate the social and healthcare impact of the "Dementia Operations Center (COD)" as a resource for people with dementia, caregivers, and healthcare and social-care professionals. The Dementia Operations Center (COD) is the central hub of the "Ricor-Dare" project. It serves as a key point of contact for dementia-related inquiries, facilitating early intervention by directing patients, caregivers, and healthcare professionals to the appropriate services within the territorial network. The COD receives referrals from healthcare providers such as general practitioners (GPs), hospitals, nursing homes, social services, and directly from patients, caregivers, or citizens. The initial contact is made via phone, and based on an analysis of the caller's needs, further physical consultations may be recommended at the COD's information desk. With a thorough mapping of the local healthcare and social service network, COD aims to meet the needs of patients, caregivers, and professionals by providing guidance on the best path for cognitive decline management. This includes assistance with the recommended pathway, non-pharmacological treatments, and caregiver support. The COD also provides information on local healthcare services, such as CCDD, nursing homes, home care, social services, and legal processes like disability procedures. The first contact with COD is through a phone number, answered by trained psychologists or staff. If necessary, callers are referred to the physical COD desk for further evaluation.
  5. Evaluate the impact of awareness and education activities on dementia. The goal is to promote social and cultural actions that improve inclusivity for people with dementia within the community. Awareness initiatives will be delivered through three annual events targeting citizens, third-sector personnel (e.g., police, firefighters), and middle and high school students.
  6. Evaluate the effectiveness of training activities for healthcare and social care professionals. The objective is to assess the effectiveness of these training programs in enhancing professionals' understanding of dementia and their attitudes toward patients and caregivers. The training, provided within the Cariplo "Welfare in Aging" project - "Ricor-Dare: Integrated Territorial Dementia Network," includes annual sessions led by experts, tailored to different roles (e.g., GPs, pharmacists, nurses, healthcare assistants). To measure the training's effectiveness, participants will complete the Dementia Knowledge-20 (DK-20) and the Approaches to Dementia Questionnaire (ADQ) before (T0) and after (T1) the training. Additionally, a survey will assess the perceived utility and relevance of the training content in clinical practice.
02

Conditions studied

  • Dementia
  • Mild Cognitive Impairment

Keywords

  • Case-finding
  • Dementia
  • Mild Cognitive Impairment
  • Memory Clinic
  • Center for Cognitive Disorders and Dementia
  • Non-pharmacological intervention
  • Caregiver
  • Burden
03

In context

Dementia

2,372 studies on the registry are indexed under Dementia; 574 are open to participants now.

This study's planned enrollment of 490 is above the median of 90 across 1,758 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

IRCCS National Neurological Institute "C. Mondino" Foundation is the lead sponsor of 57 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For the Primary Outcome the inclusion criteria are:

  • Age 50 or older
  • Assessment conducted using GPcog/ACE-III depending on the setting
  • No prior diagnosis of cognitive decline
  • Ability to understand the study objectives and sign an

For the Primary Outcome the exclusion criteria are:

  • Age under 50
  • Presence of a diagnosis of cognitive decline
  • Limited knowledge of the Italian language

For the secondary outcome the inclusion criteria are:

Patient:

  • All patients/people who are included in one of the actions provided through the "Ricor-Dare" Project or who are attending a visit scheduled in the clinical-care pathway of the CDCD Fondazione Mondino Pavia or Lomellina;
  • Ability to understand the aims of the study and to sign an informed consent

Caregiver:

  • Age equal to or greater than 18 years
  • Informal caregiver of a family member with a suspected or confirmed diagnosis of dementia who is included in one of the actions provided through the "Ricor-Dare" project or who are attending a visit scheduled in the clinical-care pathway of the CDCD;
  • Acceptance of informed consent and voluntary participation in the study.

Healthcare professionals:

  • All healthcare and social healthcare professionals (GPs, pharmacists, nurses, nurses auxiliary) who practice in the cities of Pavia and Vigevano who participate in the project and agree to undergo assessments and training;
  • Acceptance of informed consent and voluntary participation in the study.

Fo the Secondary Outcome the exclusion criteria are:

Patient:

  • Inability to understand the aims of the study and to sign an informed consent

Caregiver:

  • Age under 18
  • Formal caregivers, i.e. any person who provides assistance to the patient in exchange for payment of a fee;
  • Caregivers with limited knowledge of the Italian language.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
490 participants (estimated)

Study arms

  • Other
    Detection of people reporting cognitive concerns

    Other: Case-finding for Neurocognitive Disorders

Interventions

  • OtherCase-finding for Neurocognitive Disorders

    The intervention targets individuals reporting cognitive concerns without a prior diagnosis of MCI or dementia, with participants accessing three different settings for evaluation. The first setting involves General Practitioner (GP) offices, where GPs, trained in dementia risk factors and cognitive assessment tools (such as GPcog), will identify at-risk patients and refer them for further evaluation at a Center for Cognitive Disorders and Dementia (CCDD). The second setting is the Dementia Operations Center (COD) Information Desk, a public service where neuropsychologists assess citizens who independently report cognitive disturbances. The third setting includes Open Days, public events aimed at detecting early signs of cognitive decline, where neuropsychologists will assess participants using the Addenbrooke's Cognitive Examination-III (ACE-III) and the LIBRA Index. Individuals identified as at-risk in any of the three settings will be referred for further evaluation at a CCDD.

06

What researchers measure

Primary outcomes

  1. Effects of the case-finding strategy for the early detection of dementia in its prodromal or initial stages.

    The number of individuals, from the three case-finding settings, diagnosed at the CCDD with Mild Cognitive Impairment (MCI) or dementia within 26 months following assessment at case-finding compared to the total number of people identified as positive cases through GPcog and/or ACE-III and assessed within the three different case-finding settings.

    Time frame: Up to 26 months

Secondary outcomes

  1. The impact of the new CCDD on clinical care in an area that previously lacked such services.

    Number of patients managed at the new CDCD during the study period, all of whom underwent a baseline neurological examination, a comprehensive neuropsychological assessment, and a follow-up neurological evaluation.

    Time frame: Up to 26 months

  2. Patient and caregiver satisfaction with accessing the new CCDD.

    Number of completed satisfaction questionnaires from both patients and caregivers and their satisfaction regarding waiting times for the first medical appointments, satisfaction with the initial consultation, fulfillment of needs, and quality of services provided. For each item minimum score is 1 and maximum score is 5, where a higher score indicates higher satisfaction.

    Time frame: Up to 26 months

  3. The impact of the diagnostic-care pathway for caregivers at CCDD and "Ricor-Dare" project.

    Number of caregivers who completed the initial and final assessments and received support interventions. The efficacy of these interventions is assessed by measuring changes in caregiver burden using the validated Zarit Burden Interview. The minimum score is 0 and the maximum score is 88, where a higher score indicates a greater caregiver burden.

    Time frame: Up to 26 months

  4. The impact of the "Dementia Operations Center (COD)" pathway of the "Ricor-Dare" project.

    Number of requests received and successfully addressed through the Dementia Operations Center (COD) pathway of the 'Ricor-Dare' project.

    Time frame: Up to 26 months

  5. The impact of education activities on dementia promoted by the "Ricor-Dare" project.

    Number of people reached.

    Time frame: Up to 26 months

  6. Effectiveness of training activities for healthcare and social care professionals promoted by the "Ricor-Dare" project.

    Number of healthcare and social care professionals participating in the training activities. The efficacy of these training activities is assessed by measuring changes in knowledge by the validated Dementia Knowledge-20 questionnaire (DK-20). The minimum score is 0 and the maximum score is 11, where a higher score indicates a greater knowledge of dementia.

    Time frame: Up to 26 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Shanahan N, Orrell M, Schepers AK, Spector A. The development and evaluation of the DK-20: a knowledge of dementia measure. Int Psychogeriatr. 2013 Nov;25(11):1899-907. doi: 10.1017/S1041610213001142. Epub 2013 Aug 15. PubMed 23947900 ↗
  • Pucciarelli G, Savini S, Byun E, Simeone S, Barbaranelli C, Vela RJ, Alvaro R, Vellone E. Psychometric properties of the Caregiver Preparedness Scale in caregivers of stroke survivors. Heart Lung. 2014 Nov-Dec;43(6):555-60. doi: 10.1016/j.hrtlng.2014.08.004. Epub 2014 Sep 18. PubMed 25239706 ↗
  • Chattat R, Cortesi V, Izzicupo F, Del Re ML, Sgarbi C, Fabbo A, Bergonzini E. The Italian version of the Zarit Burden interview: a validation study. Int Psychogeriatr. 2011 Jun;23(5):797-805. doi: 10.1017/S1041610210002218. Epub 2010 Dec 16. PubMed 21205379 ↗
  • Pigliautile M, Chiesi F, Stablum F, Rossetti S, Primi C, Chiloiro D, Federici S, Mecocci P. Italian version and normative data of Addenbrooke's Cognitive Examination III. Int Psychogeriatr. 2019 Feb;31(2):241-249. doi: 10.1017/S104161021800073X. Epub 2018 Jul 19. PubMed 30021668 ↗
  • Franchini F, Musicco M, Ratto F, Storti G, Shofany J, Caltagirone C, Di Santo SG. The LIBRA Index in Relation to Cognitive Function, Functional Independence, and Psycho-Behavioral Symptoms in a Sample of Non-Institutionalized Seniors at Risk of Dementia. J Alzheimers Dis. 2019;72(3):717-731. doi: 10.3233/JAD-190495. PubMed 31640092 ↗
  • Pirani A, Brodaty H, Martini E, Zaccherini D, Neviani F, Neri M. The validation of the Italian version of the GPCOG (GPCOG-It): a contribution to cross-national implementation of a screening test for dementia in general practice. Int Psychogeriatr. 2010 Feb;22(1):82-90. doi: 10.1017/S104161020999113X. Epub 2009 Nov 6. PubMed 19891815 ↗
  • Banerjee S, Wittenberg R. Clinical and cost effectiveness of services for early diagnosis and intervention in dementia. Int J Geriatr Psychiatry. 2009 Jul;24(7):748-54. doi: 10.1002/gps.2191. PubMed 19206079 ↗
  • Steiner GZ, Ee C, Dubois S, MacMillan F, George ES, McBride KA, Karamacoska D, McDonald K, Harley A, Abramov G, Andrews-Marney ER, Cave AE, Hohenberg MI. "We need a one-stop-shop": co-creating the model of care for a multidisciplinary memory clinic with community members, GPs, aged care workers, service providers, and policy-makers. BMC Geriatr. 2020 Feb 11;20(1):49. doi: 10.1186/s12877-019-1410-x. PubMed 32046657 ↗
  • Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013 Jan;9(1):63-75.e2. doi: 10.1016/j.jalz.2012.11.007. PubMed 23305823 ↗
  • Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Thalamuthu A, Andrews G, Brayne C, Matthews FE, Stephan BC, Lipton RB, Katz MJ, Ritchie K, Carriere I, Ancelin ML, Lam LC, Wong CH, Fung AW, Guaita A, Vaccaro R, Davin A, Ganguli M, Dodge H, Hughes T, Anstey KJ, Cherbuin N, Butterworth P, Ng TP, Gao Q, Reppermund S, Brodaty H, Schupf N, Manly J, Stern Y, Lobo A, Lopez-Anton R, Santabarbara J; Cohort Studies of Memory in an International Consortium (COSMIC). The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS One. 2015 Nov 5;10(11):e0142388. doi: 10.1371/journal.pone.0142388. eCollection 2015. PubMed 26539987 ↗
  • Bacigalupo I, Mayer F, Lacorte E, Di Pucchio A, Marzolini F, Canevelli M, Di Fiandra T, Vanacore N. A Systematic Review and Meta-Analysis on the Prevalence of Dementia in Europe: Estimates from the Highest-Quality Studies Adopting the DSM IV Diagnostic Criteria. J Alzheimers Dis. 2018;66(4):1471-1481. doi: 10.3233/JAD-180416. PubMed 30412486 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06983119
Lead sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Jul 11, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
May 21, 2025

Study contacts

Nicola Allegri, PhD
Contact
nicola.allegri@mondino.it
0039 0381692413
Alessia Rosi, PhD
Contact
alessia.rosi@mondino.it
0039 0381692413
Alfredo Costa, MD
study director · IRCCS National Neurological Institute "C. Mondino" Foundation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion